NICE Guidance Recommends Upstaza for AADC Deficiency
source: shutterstock

NICE Guidance Recommends Upstaza for AADC Deficiency

  In November 2022, the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) approved Upstaza (eladocagene exuparvovec) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. The product, which…

Continue Reading NICE Guidance Recommends Upstaza for AADC Deficiency